Sherven Sharma, PhD
Languages
Contact Information
Scientific Interests
Research in Dr. Sherven Sharma's laboratory is geared toward unraveling the mechanisms in the tumor microenvironment that evade host responses and promote and maintain lung tumor growth. Knowledge gained from tumor host interactions is utilized for the development of novel cellular and nanocapsule platform-based immune strategies for lung cancer therapy.
Highlighted Publications
Andersson A, Srivastava MK, Harris-White M, Huang M, Zhu L, Elashoff D, Strieter RM, Dubinett SM, Sharma S. Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res. 2011 Jun 1;17(11):3660-72.
Kar UK, Srivastava MK, Andersson A, Baratelli F, Huang M, Kickhoefer VA, Dubinett SM, Rome LH, Sharma S. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One. 2011 May 3;6(5):e18758.
Dubinett SM, Lee JM, Sharma S, Mule JJ. Chemokines: can effector cells be redirected to the site of the tumor? Cancer J. 2010 Jul-Aug;16(4):325-35.
Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, Elashoff D, Strieter RM, Dubinett SM, Sharma S. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol. 2009 Jun 1;182(11):6951-8.
Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC, Mah V, Chia D, Goodglick L, Elashoff DA, Luo J, Magyar CE, Dohadwala M, Lee JM, St John MA, Strieter RM, Sharma S, Dubinett SM. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res. 2009 Nov 15;15(22):6820-9. Epub 2009 Nov 3